1628-1629 / 2351
RTOG 0522: C-RT
±
cetuximab for stage III-IV HNSCC
•
940 pts with stage III-IV HNSCC of the larynx and pharynx
N i
ifi
t diff
i PFS OS
• o s gn can erences n
or
• Triplet patients had higher rates of grade 3-4 mucositis
d ki
ti
an s n reac ons
Ang, ASCO 2011